Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

被引:540
|
作者
Basso, AD
Solit, DB
Chiosis, G
Giri, B
Tsichlis, P
Rosen, N
机构
[1] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[3] Thomas Jefferson Univ, Kimmel Canc, Philadelphia, PA 19107 USA
[4] Cornell Univ, Weill Grad Sch Med Sci, Program Pharmacol, Philadelphia, PA 19107 USA
关键词
D O I
10.1074/jbc.M206322200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hsp90 is a chaperone required for the conformational maturation of certain signaling proteins including Raf, cdk4, and steroid receptors. Natural products and synthetic small molecules that bind to the ATP-binding pocket in the amino-terminal domain of Hsp90 inhibit its function and cause the degradation of these client proteins. Inhibition of Hsp90 function in cells causes down-regulation of an Akt kinase-dependent pathway required for D-cyclin expression and retinoblastoma protein-dependent G, arrest. Intracellular Akt is associated with Hsp90 and Cdc37 in a complex in which Akt kinase is active and regulated by phosphatidylinositol 3-kinase. Functional Hsp90 is required for the stability of Akt in the complex. Occupancy of the ATP-binding pocket by inhibitors is associated with the ubiquitination of Akt and its targeting to the proteasome, where it is degraded. This results in a shortening of the half-life of Akt from 36 to 12 h and an 80% reduction in its expression. Akt and its activating kinase, PDK1, are the only members of the protein kinase A/protein kinase B/protein kinase C-like kinase family that are affected by Hsp90 inhibitors. Thus, transduction of growth factor signaling via the Akt and Raf pathways requires functional Hsp90 and can be coordinately blocked by its inhibition.
引用
收藏
页码:39858 / 39866
页数:9
相关论文
共 50 条
  • [31] Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage
    Park, Sangkyu
    Park, Jeong-A
    Jeon, Jae-Hyung
    Lee, Younghee
    BIOMOLECULES & THERAPEUTICS, 2019, 27 (05) : 423 - 434
  • [32] Heat Shock Protein 90 (Hsp90) Expression and Breast Cancer
    Zagouri, Flora
    Bournakis, Evangelos
    Koutsoukos, Konstantinos
    Papadimitriou, Christos A.
    PHARMACEUTICALS, 2012, 5 (09): : 1008 - 1020
  • [33] Domain-mediated dimerization of the Hsp90 cochaperones harc and Cdc37
    Roiniotis, J
    Masendycz, P
    Ho, SW
    Scholz, GM
    BIOCHEMISTRY, 2005, 44 (17) : 6662 - 6669
  • [34] Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function
    Wang, Lei
    Li, Li
    Gu, Kai
    Xu, Xiao-Li
    Sun, Yuan
    You, Qi-Dong
    CURRENT DRUG TARGETS, 2017, 18 (13) : 1572 - 1585
  • [35] TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90
    Chen, GQ
    Cao, P
    Goeddel, DV
    MOLECULAR CELL, 2002, 9 (02) : 401 - 410
  • [36] Computational investigation of ginkgetin and theaflavin as potential inhibitors of heat shock protein 90 (Hsp90)
    Bhadresha, Kinjal
    Upadhyay, Vinal
    Kumar, Sivakumar Prasanth
    Pandya, Pujan
    Jain, Nayan
    Rawal, Rakesh M.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (24): : 13675 - 13681
  • [37] Inhibitors of the heat shock protein 90 (Hsp90): Orally active 8-sulfanyladenines
    Biamonte, Marco A.
    Shi, Jiandong
    Hong, Kevin
    Hurst, David C.
    Zhang, Lin
    Fan, Junhua
    Busch, David J.
    Karjian, Patricia L.
    Maldonado, Angelica A.
    Sensintaffar, John L.
    Yang, Yong-Chin
    Kamal, Adeela
    Lough, Rachel E.
    Lundgren, Karen
    Burrows, Francis J.
    Timony, Gregg A.
    Boehm, Marcus F.
    Kasibhatla, Srinivas R.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [38] Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery
    Ting Li
    Hu-Lin Jiang
    Yun-Guang Tong
    Jin-Jian Lu
    Journal of Hematology & Oncology, 11
  • [39] HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS ATTENUATE INFLAMATORY RESPONSES IN VITRO AND IN VIVO
    Madrigal-Matute, J.
    Lopez-Franco, L.
    Blanco-Colio, L.
    Munoz-Garcia, B.
    Ramos-Mozo, P.
    Egido, J.
    Martin-Ventura, J. L.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [40] Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery
    Li, Ting
    Jiang, Hu-Lin
    Tong, Yun-Guang
    Lu, Jin-Jian
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11